Rhumbline Advisers Has $14.14 Million Holdings in Maximus, Inc. $MMS

Rhumbline Advisers increased its holdings in Maximus, Inc. (NYSE:MMS) by 1.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 201,363 shares of the health services provider’s stock after buying an additional 2,345 shares during the period. Rhumbline Advisers owned 0.36% of Maximus worth $14,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in MMS. AQR Capital Management LLC increased its stake in Maximus by 177.2% during the 1st quarter. AQR Capital Management LLC now owns 1,173,329 shares of the health services provider’s stock worth $79,341,000 after acquiring an additional 750,031 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Maximus by 40.0% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,729,305 shares of the health services provider’s stock worth $117,921,000 after purchasing an additional 494,372 shares in the last quarter. Boston Partners bought a new position in shares of Maximus in the first quarter worth $20,983,000. Dimensional Fund Advisors LP raised its stake in Maximus by 20.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,695,582 shares of the health services provider’s stock valued at $115,620,000 after purchasing an additional 288,990 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Maximus during the first quarter worth about $18,586,000. 97.21% of the stock is currently owned by institutional investors.

Insider Activity at Maximus

In other news, insider Michelle F. Link sold 1,610 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total value of $146,284.60. Following the completion of the transaction, the insider directly owned 13,508 shares in the company, valued at approximately $1,227,336.88. This represents a 10.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Maximus Stock Down 0.2%

MMS stock opened at $86.09 on Friday. The firm has a 50-day moving average price of $85.68 and a 200-day moving average price of $80.01. Maximus, Inc. has a 12 month low of $63.77 and a 12 month high of $92.50. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $4.69 billion, a P/E ratio of 15.85 and a beta of 0.57.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.01). The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.34 billion. Maximus had a net margin of 5.83% and a return on equity of 24.44%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm posted $1.46 earnings per share. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. As a group, equities research analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.30 per share. The ex-dividend date is Friday, November 14th. This represents a $1.20 annualized dividend and a dividend yield of 1.4%. Maximus’s dividend payout ratio is 21.58%.

Wall Street Analysts Forecast Growth

MMS has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Maximus in a report on Wednesday. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $90.00.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.